Drafting Effective Pharmaceutical Patents Training Course

Anthony Tridico is the managing partner of Finnegan’s European office in London, United Kingdom. Dr Tridico has more than 15 years of experience in the field of intellectual property law and his practice involves diverse technical areas from biotechnology, chemical and pharmaceutical sciences to medical devices, diagnostic tools and instrumentation. A significant portion of his current practice is devoted to post-grant proceedings, appeals and oral hearings at the USPTO’s Patent Trial and Appeal Board, as well as European Patent Office (EPO) opposition and appeal procedures. Dr Tridico also focuses on international patent prosecution and portfolio management as well as strategic counselling including pre-litigation analysis, due diligence investigations, and the specialized areas of patent term extensions and Orange Book listings.

Working in Europe for much of his career, Dr Tridico has gained significant knowledge of the European Patent Convention (EPC) and the diversity of laws and practice among the European national systems. His knowledge of the European legal system and how it differs from the United States allows Dr Tridico to effectively counsel clients with global interests in intellectual property. He has also successfully represented clients in U.S. district court and multi-national patent litigations including protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations.

Dr Tridico is a frequent lecturer on intellectual property issues at various international programs and conferences targeted to the U.S. and European business community. He has spoken before numerous Fortune 500 companies and multi-national organizations throughout the world. 

Highlights

BTG Int’l Ltd. v. Kappos (E.D. Va.). Represented BTG International Ltd. in the first post-AIA 35 U.S.C. § 145 action in the District Court for the E.D. Va. on an appeal from the USPTO regarding a patent application directed to CDw52 specific antibodies.

Represents Pronova BioPharma in Hatch-Waxman litigations against two companies seeking FDA approval to market generic versions of Lovaza® which had 2011 sales of over $900 million. The district court found the asserted patent claims valid, enforceable and infringed in May 2012, thus precluding marketing of any generics until April 2017.

Professional Activities

American Intellectual Property Law Association

American Chemical Society

Sigma Xi

Select Publications

Coauthor. “Spring Update: More Lessons Learned from the New Post-Grant Proceedings,” CIPA Journal, March 2014.

Coauthor. “Novartis v. Lee: A New Method for Calculating U.S. Patent Term Adjustment,” CIPA Journal, Feb. 2014.

Coauthor. “IP5 PPH Pilot Program,” Intellectual Property Today, Jan. 2014.

Dr. Amanda Murphy is a Partner in Finnegan’s Washington, DC Office and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe. In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.

Dr. Anthony Tridico is the Managing Partner of Finnegan’s European office in London and has over 20 years of experience protecting pharmaceutical inventions. Anthony practices all aspects of intellectual property law, from strategic patent portfolio management to litigation including strategic client counselling, due diligence investigations, patent portfolio management and analysis, prosecution and drafting, and appeals and oral hearings at the Patent Trial and Appeal Board (PTAB). He also offers expertise in representing clients in the specialised areas of FDA Orange Book listing of patents, and patent term extensions. Anthony has served for over 15 years as adjunct professor at Georgetown University Law School teaching patent law and patent prosecution and he has been recognized by Intellectual Asset Management as a leading patent prosecutor in the United Kingdom and Europe in the IAM Patent 1000, and as a top IP strategist by the IAM Strategy 300. Managing Intellectual Property named him an “IP Star” in the United Kingdom.